In the U.S., the prescription drug market will actually shrink 1.2% in 2013, continuing a multiyear trend that has seen patents expire on many iconic blockbuster drugs, including the anticlotting drug Plavix last year, which was once the world's second best-selling drug. Growth is expected to slowly resume in 2014 and beyond with the expansion of healthcare coverage under the Obama administration's healthcare overhaul.
IMS' Institute for Healthcare Informatics calls for drug sales growth in the U.S. between 1% and 4% through 2017.
The report paints several scenarios for the U.S. market based on how the plan is implemented. If the plan achieves Obama's goal of enrolling roughly 30 million uninsured Americans—through expanding Medicaid and individuals enrolling in state insurance exchanges—total U.S. spending on prescription drugs could rise to between $420 billion and $460 billion by 2017. If the plan fails to enroll Americans in significant numbers it could contribute to a decline in demand for medication, and drug spending would be just $300 billion to $320 billion by 2017.
Last week the federal officials reported that only 106,000 people signed up for "Obamacare" in October, barely one-fifth of what officials had projected
Growth in Europe through 2017 will be flat to up 3% as governments there implement new austerity measures designed to restrain spending on brand-name drugs.
During the same period the pharmaceutical industry will see double-digit sales growth in emerging markets like China, where IMS expects medicine spending to grow 34% through 2017.
Sales in these emerging markets will mostly consist of low-cost generics which will grow to become more than 36% of global sales by 2017. Currently generics make up about 27% of the global market.
The report notes that drugmakers continue to develop a steady stream of new products, though research has shifted from blockbuster treatments for common diseases to niche drugs for rare diseases and small patient populations. Spending on these specialty medications is expected to rise 38% to between $230 and $240 billion by 2017.
Other trends highlighted in the report include:
The U.S. share of the world's prescription drug spending will fall from about 34% last year to 31% in 2017.
Spending by emerging markets, including China, will jump from 39% of the total last year to 48% in 2017.